Cargando…
Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the occurrence of cardiovascular and renal complications in patients with type 2 diabetes mellitus (T2DM) and represent guideline‐recommended therapy in this indication. However, precise mechanisms underlying the beneficial cardiovascular effe...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590106/ https://www.ncbi.nlm.nih.gov/pubmed/32810338 http://dx.doi.org/10.1111/jch.13988 |
_version_ | 1783600731652096000 |
---|---|
author | Kario, Kazuomi Okada, Kenta Murata, Mitsunobu Suzuki, Daisuke Yamagiwa, Kayo Abe, Yasuhisa Usui, Isao Tsuchiya, Norihiro Iwashita, Chie Harada, Noriko Okawara, Yukie Ishibashi, Shun Hoshide, Satoshi |
author_facet | Kario, Kazuomi Okada, Kenta Murata, Mitsunobu Suzuki, Daisuke Yamagiwa, Kayo Abe, Yasuhisa Usui, Isao Tsuchiya, Norihiro Iwashita, Chie Harada, Noriko Okawara, Yukie Ishibashi, Shun Hoshide, Satoshi |
author_sort | Kario, Kazuomi |
collection | PubMed |
description | Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the occurrence of cardiovascular and renal complications in patients with type 2 diabetes mellitus (T2DM) and represent guideline‐recommended therapy in this indication. However, precise mechanisms underlying the beneficial cardiovascular effects of SGLT2 inhibitors are not fully understood. This study investigated the effects of the SGLT2 inhibitor, luseogliflozin, on arterial properties and home blood pressure (BP) in patients with T2DM. This multicenter, single‐arm study enrolled adults with T2DM, glycosylated hemoglobin (HbA1c) 6.5%‐8.9% in the previous 4 weeks, and an indication for new/additional antidiabetic therapy. Luseogliflozin 2.5 mg/d was given for 12 weeks. Primary outcome was change in cardio‐ankle vascular index (CAVI) from baseline to Week 4 and Week 12. Home and office BP, BP variability, and metabolic parameters were secondary endpoints. Forty‐seven patients (mean age 63.5 ± 10.7 years) treated with luseogliflozin were included in the full analysis set. CAVI did not change significantly from baseline (mean [95% confidence interval] 8.67 [8.37‐8.97]) to Week 12 (8.64 [8.38‐8.91]; P = .750), but there were significant reductions from baseline in morning home BP, HbA1c, body weight, body mass index, and serum uric acid levels during luseogliflozin therapy. The reduction in morning home systolic BP was ≥ 5 mm Hg and was independent of baseline BP and BP control status. In conclusion, there was no change in arterial stiffness (based on CAVI) during treatment with luseogliflozin, but changes in BP and metabolic parameters were consistent with the known beneficial effects of SGLT2 inhibitors in T2DM. |
format | Online Article Text |
id | pubmed-7590106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75901062020-10-30 Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study Kario, Kazuomi Okada, Kenta Murata, Mitsunobu Suzuki, Daisuke Yamagiwa, Kayo Abe, Yasuhisa Usui, Isao Tsuchiya, Norihiro Iwashita, Chie Harada, Noriko Okawara, Yukie Ishibashi, Shun Hoshide, Satoshi J Clin Hypertens (Greenwich) Sglt2 Inhibition Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the occurrence of cardiovascular and renal complications in patients with type 2 diabetes mellitus (T2DM) and represent guideline‐recommended therapy in this indication. However, precise mechanisms underlying the beneficial cardiovascular effects of SGLT2 inhibitors are not fully understood. This study investigated the effects of the SGLT2 inhibitor, luseogliflozin, on arterial properties and home blood pressure (BP) in patients with T2DM. This multicenter, single‐arm study enrolled adults with T2DM, glycosylated hemoglobin (HbA1c) 6.5%‐8.9% in the previous 4 weeks, and an indication for new/additional antidiabetic therapy. Luseogliflozin 2.5 mg/d was given for 12 weeks. Primary outcome was change in cardio‐ankle vascular index (CAVI) from baseline to Week 4 and Week 12. Home and office BP, BP variability, and metabolic parameters were secondary endpoints. Forty‐seven patients (mean age 63.5 ± 10.7 years) treated with luseogliflozin were included in the full analysis set. CAVI did not change significantly from baseline (mean [95% confidence interval] 8.67 [8.37‐8.97]) to Week 12 (8.64 [8.38‐8.91]; P = .750), but there were significant reductions from baseline in morning home BP, HbA1c, body weight, body mass index, and serum uric acid levels during luseogliflozin therapy. The reduction in morning home systolic BP was ≥ 5 mm Hg and was independent of baseline BP and BP control status. In conclusion, there was no change in arterial stiffness (based on CAVI) during treatment with luseogliflozin, but changes in BP and metabolic parameters were consistent with the known beneficial effects of SGLT2 inhibitors in T2DM. John Wiley and Sons Inc. 2020-08-18 /pmc/articles/PMC7590106/ /pubmed/32810338 http://dx.doi.org/10.1111/jch.13988 Text en ©2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Sglt2 Inhibition Kario, Kazuomi Okada, Kenta Murata, Mitsunobu Suzuki, Daisuke Yamagiwa, Kayo Abe, Yasuhisa Usui, Isao Tsuchiya, Norihiro Iwashita, Chie Harada, Noriko Okawara, Yukie Ishibashi, Shun Hoshide, Satoshi Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study |
title | Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study |
title_full | Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study |
title_fullStr | Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study |
title_full_unstemmed | Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study |
title_short | Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study |
title_sort | effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: the multicenter, exploratory luscar study |
topic | Sglt2 Inhibition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590106/ https://www.ncbi.nlm.nih.gov/pubmed/32810338 http://dx.doi.org/10.1111/jch.13988 |
work_keys_str_mv | AT kariokazuomi effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT okadakenta effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT muratamitsunobu effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT suzukidaisuke effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT yamagiwakayo effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT abeyasuhisa effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT usuiisao effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT tsuchiyanorihiro effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT iwashitachie effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT haradanoriko effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT okawarayukie effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT ishibashishun effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy AT hoshidesatoshi effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy |